There is described (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid, or a salt or ester thereof, having substantially limited amounts of specific impurities associated with the synthesis and purification of the (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid.

The present invention provides an NSAID such as ibuprofen or flurbiprofen, or a pharmaceutically acceptable salt thereof for use in the topical treatment of coughs, especially dry coughs.

The present invention relates to stable topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and chlorhexidine or salts thereof. More particularly, the present invention relates to a stable oral topical aqueous pharmaceutical composition of this combination having desired levels of dissolution rate, solubility, enhanced taste and absorption from mucosal surface, comprising mint oil or eucalyptus oil and wherein the pH of the solution is...

An ingestible particulate composition including at least one compound selected from the group consisting of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol, and benzydamine and one or more bioadhesive materials. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for ad...

The present invention relates to a capsule formulation comprising together with an NSAID with anti-inflammatory analgesic and antipyretic activities an H2 receptor antagonist used for preventing or minimizing gastrointestinal side effects caused by NSAID.

The present invention is related to a pharmaceutical formulation which comprises NSAID having antiinflamatory analgesic and antipyretic effect together with an H2 receptor antagonist used for preventing and minimizing the gastrointestinal side effects of NSAID. According to another aspect the present invention relates to the fact that the pharmaceutical formulation comprising NSAID as the first drug substance and H2 receptor antagonist as second active substance is a novel solid oral multilayer ...